Last reviewed · How we verify
NCT06154707
Clinical Controlled Study on the Efficacy of Denosumab in Treating Osteoporosis in the Domestic Population and Its Impact on Sarcopenia-related Outcomes
Phase 3 trial testing Denosumab Injection in Sarcopenia in 86 participants. Status unknown.
31 December 2024
Quick facts
| Lead sponsor | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology |
|---|---|
| Phase | Phase 3 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 86 |
| Start date | 1 February 2024 |
| Primary completion | 31 December 2024 |
| Estimated completion | 1 March 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- Denosumab Injection
- Normal saline injection (1.0ml/ branch)
Conditions studied
- Sarcopenia — all drugs for Sarcopenia →
- Osteoporosis — all drugs for Osteoporosis →
- Denosumab — all drugs for Denosumab →
Sponsor
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Who can join
40 and older, any sex, with Sarcopenia or Osteoporosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Through the method of a clinical randomized controlled trial, patients meeting the study criteria are randomly assigned to either the Denosumab treatment group or a placebo group. After a treatment period of 12 months, the differences in osteoporosis and sarcopenia-related baseline assessment changes between the two groups are compared. This is to explore the effect of Denosumab in treating osteoporosis and its impact on sarcopenia. The goal is to evaluate the efficacy of Denosumab in treating osteoporosis in the domestic population and its related impact on sarcopenia, with the aim of providing an effective treatment option for the domestic population suffering from 'osteoporosis-sarcopenia syndrome.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Denosumab for Primary Osteoporosis and Its Impact on Sarcopenia in the Chinese Population: Insights from Clinical Evidence and RANKL Pathway Mendelian Randomization.
Li S, Hu S, Zheng X, Ku X, et al · · 2025 · cited 2× · PMID 41268337 · DOI 10.2147/cia.s547803 -
Denosumab ameliorates muscle indices in Chinese osteoporosis patients through clinical and bioinformatic evidence of RANKL in sarcopenia.
Li S, Hu S, Zheng X, Ku X, et al · · 2026 · PMID 41660235 · DOI 10.1016/j.isci.2025.114509
Verify or expand the search:
- PubMed search for NCT06154707
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Denosumab Injection
Trials testing the same drug.
- NCT04467983 — Abaloparatide Added to Ongoing Denosumab vs Continued Denosumab Alone · Phase 4 · active not recruiting
- NCT05598606 — Denosumab vs Zoledronate After Vertebroplasty · Phase 4 · completed
- NCT04547348 — The DENOCHARCOT Trial · Phase 3 · recruiting
- NCT04231682 — A Study to Evaluate Efficacy and Safety of Denosumab for Prevention and Treatment of Osteoporosis in 1st Time Liver Tran · Phase 2 · withdrawn
Other recruiting trials for Sarcopenia
Currently open trials in the same condition.
- NCT07500376 — Multimodal Nutritional and Sarcopenia Assessment for Risk Stratification in Lung Cancer Surgery · recruiting
- NCT07456956 — HIIT vs MCIT for Stroke-Related Sarcopenia in Ischemic Stroke · NA · recruiting
- NCT07398495 — Multimodal Training Effects in Middle-Aged and Older Adults With Diabetic Sarcopenia · NA · recruiting
- NCT07494916 — Effects of Functional Task Training on Muscle Health and Function in Older Adults With Sarcopenia · NA · active not recruiting
- NCT07426159 — AI-Guided Sarcopenia Risk Assessment and Detection · NA · active not recruiting
Other Union Hospital, Tongji Medical College, Huazhong University of Science and Technology trials
Trials by the same sponsor.
- NCT07521124 — ABC Maintenance Therapy for AML · NA · not yet recruiting
- NCT07497243 — X-ray Assisted Diagnostic System · not yet recruiting
- NCT07520123 — Union-FAST: An Intelligent-Agent Intervention to Increase Antiviral Treatment Uptake in Diagnosed-but-Untreated Hepatiti · NA · not yet recruiting
- NCT06970262 — FMT for Lung and Associated-organ Rescue Efficacy in ARDS Patients · NA · recruiting
- NCT07509424 — Neoadjuvant Short-course Radiotherapy Followed by a Combination of Disitamab Vedotin, Sintilimab, and Capecitabine in Lo · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06154707 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- Last refreshed: 16 August 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06154707.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing